News Releases | Portage Biotech

Year

20 Sep '23

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

WESTPORT, Conn. , Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a panel

05 Sep '23

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

WESTPORT, Conn. , Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced that it has entered into a clinical trial collaboration agreement

30 Aug '23

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Company focused on accelerating clinical programs for PORT-2, PORT-6, and PORT-7 WESTPORT, Conn. , Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination,

31 Jul '23

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Company poised to accelerate accrual in all clinical programs as it activates numerous sites across multiple U.S. cities and abroad and takes over sponsorship from the investigator-led program Updated interim data for lead iNKT engager, PORT-2, presented at the 2023 ASCO Annual Meeting showed early

26 Jun '23

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

WESTPORT, Conn. , June 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that it has dosed the first patient in its Phase 1a trial,

05 Jun '23

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction of several target lesions Based on the favorable safety and tolerability data at all doses tested to date, the Company intends to expand Phase 1 portion of the trial to evaluate higher dose levels;

01 Jun '23

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Ian Walters, M.D. to serve as expert panelist discussing the future of immune checkpoint inhibitors WESTPORT, Conn. , June 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and

26 Apr '23

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

WESTPORT, Conn. , April 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced the acceptance of a poster presentation at the American Society of

07 Mar '23

Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference

WESTPORT, Conn. , March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will be presenting virtually at

01 Mar '23

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

- Enrollment ongoing in IMPORT-201 Phase 1/2 trial of PORT-2 in Melanoma and Non-Small Cell Lung Cancer - Company on track to initiate Phase 1 portion of ADPORT-601 trial by end of 2Q23 - Company to Host a Key Opinion Leader Event on Targeting Adenosine Pathway in Cancer WESTPORT, Conn.

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12